calcium heparin (Calciparine)

09/01/1989 - "Significant improvement in protection against postoperative deep vein thrombosis, assessed by venography, was observed in the adjusted group undergoing hip replacement (P = 0.013) and overall in both groups (P = 0.017) compared with a conventional fixed dose subcutaneous regimen (calcium heparin 5000 units, 8-hourly). "
10/01/1987 - "Adjusted subcutaneous calcium heparin may be an effective and safe alternative to continuous intravenous calcium heparin in the initial treatment of acute proximal deep vein thrombosis."
06/03/1978 - "A double-blind controlled clinical trial of the efficacy of the prophylactic subcutaneous administration of calcium heparin in preventing deep vein thrombosis has been conducted in 50 patients with a fractured neck of the femur. "
06/01/1992 - "To assess the efficacy and safety of dermatan sulphate (MF 701) in preventing postoperative deep vein thrombosis (DVT), 324 patients aged 40 years or over undergoing elective major general surgical operations were included in a randomized trial comparing MF 701 (100 mg intramuscularly once a day) with unfractionated calcium heparin (UFH, 5000 units subcutaneously three times daily). "
07/01/2001 - "Subcutaneous calcium heparin was immediately administered to prevent deep venous thrombosis. "

07/01/1974 - "[Clinical studies on thrombosis prevention using calciparin in surgery]."
10/15/1991 - "Each immuno-potent drug was administered for six days before the thrombus induction at the same dosage (10mg/kg b.w.), and the Calciparin, used as treatment of the thrombosis, was administered two hours after the thrombus induction at the dose of 1mg/kg b.w. "
07/01/1989 - "The Authors investigated the lipidometabolic effects of calcium heparin in order to assess if the antiatherogenic usefulness of the drug, recently demonstrated in the treatment of thrombosis and myocardial reinfarction, may be linked to its hypolipemiant property in addition to the antithrombotic one. "
02/29/1988 - "[Use of calcium heparin in the prevention of thrombosis after arterial revascularization surgery]."
05/09/1987 - "Of 49 patients who received subcutaneous calcium heparin, two showed an increase in thrombus size, while eight showed complete lysis. "

10/01/1982 - "The relative efficacy of sodium and calcium heparin in preventing venous thromboembolism and their relative side-effects were studied in 234 high-risk patients in a randomised, double-blind, placebo-controlled trial. "
10/01/1982 - "Comparison of sodium and calcium heparin in prevention of venous thromboembolism."
04/08/1988 - "The safety and efficacy of a low molecular weight heparin fragment Kabi 2165, given in the dose 2,500 anti-Xa units once daily, in preventing postoperative venous thromboembolism, was assessed against calcium heparin in the dose 5,000 IU twice daily, in a multicenter double blind randomized study. "

05/01/1988 - "In the group treated with calcium heparin 2 cases of clinically and radiologically diagnosed pulmonary embolism and 4 cases of DVT were observed. "
07/01/1988 - "During the study 4 (0.65%) pulmonary embolism were found, 1 (0.32%) in the group treated with LMW heparin and 3 (1%) in the group treated with calcium heparin. "
07/01/1993 - "Pulmonary embolism (PE) was ascertained by angiography in 1 patient (0.18%) in the enoxaparin group and in 2 patients (0.36%) in the calcium heparin one. "
12/01/1988 - "In the Calciparine group, two patients (5%) developed postoperative pulmonary embolism but none developed it in the Fragmin group. "
11/01/1988 - "Pulmonary embolism occurred in 2 of 960 patients (0.2 per cent) treated with Fraxiparin and in 5 of 936 patients (0.5 per cent) treated with calcium heparin. "

07/22/1989 - "Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. "
12/01/1993 - "2830 evaluable patients (2090 M, 709 F, mean age 63 years) who had in the previous 2 years a myocardial infarction were treated subcutaneously with calcium heparin (Calciparina Italfarmaco, 0.5 ml prefilled syringe) at the daily dosage of 12.500 U. "
12/01/1997 - "In order to assess the efficacy of 3-month subcutaneous treatment with calcium heparin 12,500 IU twice daily in preventing left ventricular thrombosis and its complications a prospective, controlled, randomized trial was carried out in 204 patients with acute anterior myocardial infarction consecutively enrolled in seven Italian hospitals. "
12/01/1997 - "Mean-term calcium heparin treatment in acute transmural anterior myocardial infarction: effects on left ventricular thrombosis and its complications."
03/01/1992 - "[Left ventricular thrombosis in acute myocardial infarction: incidence, complications, and clinical effects of calcium heparin]."